

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity

Rüdiger Groß^{a,*}, Michelle Zanoni^{a,*}, Alina Seidel^{a,*}, Carina Conzelmann^a, Andrea Gilg^a, Daniela Krnavek^a, Sümeyye Erdemci-Evin^a, Benjamin Mayer^b, Markus Hoffmann^{c,d}, Stefan Pöhlmann^{c,d}, Alexandra Beil^e, Joris Kroschel^c, Bernd Jahrsdörfer^{f,g}, Hubert Schrezenmeier^{f,g}, Frank Kirchhoff^a, Jan Münch^{a,h}, Janis A. Müller^{a,#}

^a Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany

^b Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany

^c Infection Biology Unit, German Primate Center – Leibniz Institute for Primate Research, Göttingen, Germany

^d Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany

^e Central Department for Clinical Chemistry, University Hospital Ulm, 89081 Ulm, Germany

^f Institute for Transfusion Medicine, Ulm University, 89081 Ulm, Germany

^g Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Services Baden-Württemberg-Hessen and University Hospital Ulm, 89081 Ulm, Germany

^h Core Facility Functional Peptidomics, Ulm University Medical Center, 89081 Ulm, Germany

* authors contributed equally

Correspondence: Janis A. Müller (Janis.mueller@uni-ulm.de)

26
27 **Abstract:**
28
29 **Background**
30 Heterologous prime-boost schedules with vector- and mRNA-based COVID-19 vaccines are already
31 administered, but immunological responses and elicited protection have not been reported.
32
33 **Methods**
34 We here analyzed a cohort of 26 individuals aged 25-46 (median 30.5) years that received a ChAdOx1
35 nCoV-19 prime followed by a BNT162b2 boost after an 8-week interval for reactogenicity, antibody
36 responses and T cell reactivity.
37
38 **Results**
39 Self-reported solicited symptoms after ChAdOx1 nCoV-19 prime were in line with previous reports and
40 less severe after the BNT162b2 boost. Antibody titers increased significantly over time resulting in strong
41 neutralization titers 2 weeks after the BNT162b2 boost. Neutralizing activity against the prevalent strain
42 B.1.1.7 was 3.9-fold higher than in individuals receiving homologous BNT162b2 vaccination, only 2-fold
43 reduced for variant of concern B.1.351, and similar for variant B.1.617. In addition, CD4⁺ and CD8⁺ T
44 cells reacted to SARS-CoV-2 spike peptide stimulus 2 weeks after the full vaccination.
45
46 **Conclusions**
47 The heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination regimen is not associated
48 with serious adverse events and results in a potent humoral immune response and elicits T cell reactivity.
49 Variants of concern B.1.1.7, B.1.351 and B.1.617 are potently neutralized by sera of all participants.
50 These results suggest that this heterologous vaccination regimen is at least as immunogenic and protective
51 as homologous vaccinations.
52
53

54 **Introduction:**

55
56 The first cases of the coronavirus disease 2019 (COVID-19) were reported to the World Health
57 Organization on December 31st 2019¹, and within 93 days the causative severe acute respiratory syndrome
58 coronavirus 2 (SARS-CoV-2) had infected over 1 million people worldwide ². Only 250 days later, the
59 first person received a COVID-19 vaccine outside a clinical trial, and vaccinations are now considered a
60 key strategy for ending the pandemic³. Approved vaccines include the adenovirus-based ChAdOx1 nCoV-
61 19 (Vaxzevria, AstraZeneca) and mRNA-based BNT162b2 (Comirnaty, BioNTech/Pfizer), which induce
62 humoral and cellular immunological responses ⁴⁻⁷, showed high efficacy in clinical trials ^{8,9} and a high
63 degree of protection from COVID-19 in real-world settings^{10,11}. However, the occurrence of rare
64 thrombotic events after ChAdOx1 nCoV-19 vaccinations, especially in individuals younger than 60 years,
65 associated with the generation of auto-platelet factor 4 antibodies halted the administration of the second
66 dose of ChAdOx1 nCoV-19 for this group ¹²⁻¹⁴. As a consequence, several public health agencies now
67 recommend that boost vaccination for these individuals is carried out in a heterologous regimen with an
68 mRNA vaccine ¹⁵. Recent studies indicate that such a heterologous schedule is associated with more
69 severe ¹⁶ or similar ¹⁷ solicited symptoms, and preclinical data suggests immunogenicity to be similar to or
70 higher than in animals receiving homologous mRNA-based prime-boost vaccination¹⁸. However, evidence
71 for immunogenicity of such a regimen in humans and for optimal timing between prime and boost is
72 lacking. In addition, it is currently unclear to which degree a heterologous vaccination regimen confers
73 protection against the variants of concern¹⁹.

74 Here, we studied a cohort of 26 individuals (16 female, 10 male; median age 30.5, range 25-46) (Table I)
75 who received ChAdOx1 nCoV-19 prime and, due to changing recommendations in Germany, ¹⁵ a
76 BNT162b2 boost vaccination with a 56 day interval and evaluated solicited adverse reactions, humoral
77 and cellular immune responses.

78

79

80 **Table I: Study participants**

	Total	m	f
Participants	26	10	16
Age median	30.5 (25-46)	32 (26-44)	30.5 (25-46)
Prior SARS-CoV-2 infection	1	0	1
Platelet factor 4 autoantibodies (determined in ²⁰)	0	0	0

81

82

83

84

85

86 **Materials and Methods:**

87

88 **Collection of serum and PBMC samples**

89

90 Blood samples from individuals were obtained after recruitment of participants and written informed
91 consent as approved by the ethics committee of Ulm university (99/21). Participants received a
92 heterologous vaccination regimen because after their ChAdOx1 nCoV-19 prime vaccination, the German
93 Standing Committee on Vaccination (STIKO) had changed the recommendation for individuals < 60 years
94 of age to receive an mRNA vaccine as boost vaccination to avoid risk of thrombotic complications^{12,15}. At
95 days -2/0 before vaccination, days 15-16, 30-37, 53-57 after ChAdOx1 nCoV-19 vaccination, and days 6-
96 11 and 14-19 after heterologous BNT162b2 boost (days 64-65 and 72-73 after ChAdOx1 nCoV-19,
97 respectively), blood was drawn into S-Monovette® Serum Gel (Sarstedt) or S-Monovette® K3 EDTA tubes.
98 Sera from individuals vaccinated twice with BNT162b2 were obtained 13-15 days after the second dose
99 under approval by the ethics committee of Ulm university (31/21); these sera were previously described
100 and re-analyzed for this study²¹. Serum Gel collection tubes were centrifuged at 1,500 × g at 20°C for 15
101 min, aliquoted stored at -20°C until further use. Peripheral blood mononuclear cells (PBMCs) were
102 obtained from EDTA tubes using density gradient centrifugation by Pancoll human (Pan Biotech,
103 Germany), and erythrocytes removed by ACK lysis buffer (Lonza, Walkersville, MD, U.S.A). Mononuclear
104 cells were counted for viability using a Countess II Automated Cell Counter (Thermo Fisher) with trypan
105 blue stain and were cryopreserved in aliquots of up to 1x10⁷ cells in 10% DMSO in heat-inactivated FCS.

106

107 **Vaccine reactogenicity**

108

109 Solicited adverse reactions (SAR) were self-reported by the participants via questionnaire following
110 prime and boost vaccination. Participants were asked to list symptoms, their duration (< 1 h, few hours,
111 one day or more than one day) and severity (mild (grade 1), moderate (grade 2), severe (grade 3).
112 Grading criteria were adapted from the US Department of Health and Human Services CTCEA (Common
113 Terminology Criteria for Adverse Events, v4.03)²², with grade 1-2 being considered for some symptoms,
114 grade 1-3 for most. For calculation of cumulative SAR (cSAR) scores, the grades of all symptoms listed
115 were summed up, with an additional score point added for symptoms experienced for more than one
116 day (0-4).

117

118 **Determination of antibody titers**

119

120 IgG and IgA levels in serum were determined by anti-SARS-CoV-2 assay (Euroimmun), an ELISA which
121 detects antibodies against the SARS-CoV-2 S1 spike domain. The assay was performed according to the
122 manufacturer's instructions. Briefly, serum samples were diluted 10-fold in sample buffer and pipetted

123 into rSARS-CoV-2 spike precoated strips of eight single wells of a 96-well microtiter. After incubation for
124 60 min at 37°C, wells were washed three times, peroxidase-labeled anti-IgG or anti-IgA added and
125 incubated. After 30 min, three additional washing steps were performed before substrate was added
126 and incubated for 15-30 min in the dark. Thereafter, stop solution was added, and optical density (OD)
127 values measured on a POLARstar Omega plate reader (BMG LABTECH, Ortenberg, Germany) at 450 nm
128 corrected for 620 nm. Finally, OD ratios were calculated based on the sample and calibrator OD values,
129 where a ratio <0.8 was considered to be negative and >1.1 to be positive. To quantify antibody
130 responses, IgG and IgM were measured as units per ml (U/ml) that correlates with the WHO standard
131 unit for the SARS-CoV-2 binding antibody units per ml (BAU/ml). To this end, serum was analyzed using
132 the commercial electrochemiluminescence Elecsys Anti-SARS-CoV-2 S immunoassay (Roche, Mannheim,
133 Germany) by a cobas® e801 immunoassay analyzer according to the manufacturer's instructions (Roche).

134

135 **Surrogate SARS-CoV-2 neutralization test**

136

137 Prevention of SARS-CoV-2 spike RBD interaction with ACE2 by sera was evaluated by SARS-CoV-2
138 Surrogate Virus Neutralization Test Kit (GenScript) according to the manufacturer's instructions. To this
139 end, sera were incubated with a peroxidase-conjugated RBD fragment and the mixture added to a
140 human ACE-2 coated plate, and unbound RBD washed away. Thereafter, substrate was added and the
141 reaction stopped by stopping reagent. ODs at 450 nm were measured at a microplate reader. The
142 inhibition score compared to the negative control was calculated as percentages. Scores <20% were
143 considered negative and scores >20% positive.

144

145 **Cell culture**

146

147 Vero E6 (African green monkey, female, kidney; CRL-1586, ATCC, RRID:CVCL_0574) cells were grown in
148 Dulbecco's modified Eagle's medium (DMEM, Gibco) which was supplemented with 2.5% heat-
149 inactivated fetal calf serum (FCS), 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 1
150 mM sodium pyruvate, and 1x non-essential amino acids. HEK293T (human, female, kidney; ACC-635,
151 DSMZ, RRID: CVCL_0063) cells were grown in DMEM with supplementation of 10% FCS, 100 units/ml
152 penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine. All cells were grown at 37°C in a 5% CO₂
153 humidified incubator.

154

155 **Preparation of pseudotyped particles**

156

157 Expression plasmids for vesicular stomatitis virus (VSV, serotype Indiana) glycoprotein (VSV-G) and SARS-
158 2-S variants B.1.1.7, B.1.351 and B.1.617 (codon-optimized; with a C-terminal truncation of 18 amino
159 acid residues) have been described elsewhere^{19,21}. Transfection of cells was carried out by Transit LT-1
160 (Mirus). Rhabdoviral pseudotype particles were prepared as previously described²³. A replication-

161 deficient VSV vector in which the genetic information for VSV-G was replaced by genes encoding two
162 reporter proteins, enhanced green fluorescent protein and firefly luciferase (FLuc), VSV*ΔG-FLuc²⁴
163 (kindly provided by Gert Zimmer, Institute of Virology and Immunology, Mittelhäusern, Switzerland)
164 (Berger Rentsch and Zimmer, 2011) was used for pseudotyping. One day after transfection of HEK293T
165 cells to express the viral glycoprotein, they were inoculated with VSV*ΔG-FLuc and incubated for 1-2 h at
166 37°C. Then the inoculum was removed, cells were washed with PBS and fresh medium added. After 16-
167 18 h, the supernatant was collected and centrifuged (2,000 × g, 10 min, room temperature) to clear
168 cellular debris. Cell culture medium containing anti-VSV-G antibody (I1-hybridoma cells; ATCC no. CRL-
169 2700) was then added to block residual VSV-G-containing particles. Samples were then aliquoted and
170 stored at -80°C.

171

172 **Pseudovirus neutralisation assay**

173

174 For pseudovirus neutralisation experiments, VeroE6 were seeded in 96-well plates one day prior (6,000
175 cells/well). Heat-inactivated (56°C, 30 min) sera were serially titrated in PBS, pseudovirus stocks added
176 (1:1, v/v) and the mixtures incubated for 30 min at 37°C before being added to cells. After an incubation
177 period of 16-18 h, transduction efficiency was analyzed. For this, the supernatant was removed, and cells
178 were lysed by incubation with Cell Culture Lysis Reagent (Promega) at room temperature. Lysates were
179 then transferred into white 96-well plates and FLuc activity was measured using a commercially available
180 substrate (Luciferase Assay System, Promega) and a plate luminometer (Orion II Microplate
181 Luminometer, Berthold). For analysis of raw values (RLU/s), background signal of an uninfected plate was
182 subtracted and values normalized to pseudovirus treated with PBS only. Results are given as serum
183 dilution resulting in 50% virus neutralization (NT50) on cells, calculated by nonlinear regression
184 ([Inhibitor] vs. normalized response -- Variable slope) in GraphPad Prism Version 9.1.1.

185

186 **Determination of CD4⁺ and CD8⁺ T SARS-CoV-2 spike -specific cell responses by intracellular cytokine 187 staining (ICS)**

188

189 Cryopreserved PBMCs of study participants were thawed and rested overnight at 37°C with 1 µl/ml of
190 DNase (DNase I recombinant, RNase-free (10,000 U) Roche), in RPMI medium supplemented to contain a
191 final concentration of 10% FCS (Corning Life Sciences/Media Tech Inc, Manassas, VA), 10 mM HEPES, 1x
192 MEM nonessential amino acids (Corning Life Sciences/Media Tech Inc, Manassas, VA), 1 mM Sodium
193 Pyruvate (Lonza, Walkersville, MD, U.S.A), 1mM Penicillin/Streptomycin (Pan Biotech, Germany) and 1x
194 2-Mercaptoethanol (GIBCO, Invitrogen, Carlsbad, CA, U.S.A). Stimulation of PBMCs for detection of
195 cytokine production by T cells was adapted from Kasturi *et al.*, 2020²⁵. Briefly, 1x10⁶ PBMCs were
196 cultured in 200 µl final volume in 96-well U bottom plate in the presence of anti-CD28 (1 µg/ml) and anti-
197 CD49d (1 µg/ml) [Biolegend] under the following conditions: a) negative control with DMSO, b) SARS-
198 CoV-2 spike peptide pool (1-315 peptides from Wuhan SARS-CoV-2 spike, JPT Germany) at a final
199 concentration of 2 µg/ml, c) PMA/Ionomycin. Cells were cultured for 2 hours before adding Brefeldin A
200 at 10 µg/ml (Sigma-Aldrich, St Louis, MO) for an additional 5 hours. Cells were then washed with PBS,
201 and stained for dead cells (Live/ Dead Fixable; Aqua from Thermo Fisher) in PBS at room temperature for

202 10 minutes. Without washing, cells were incubated with surface antibody cocktail (prepared in 1:1 of
203 FACS buffer and brilliant staining buffer) for 30 minutes at room temperature with BV510-anti-human
204 CD14 (clone M5E2), BV510-anti-human CD19 (clone HIB19), AF700 anti-human CD3 (clone OKT3), BV605
205 CD4 (clone OKT4), PerCP-Cy5.5 CD8 (clone RPA-T8) from Biolegend. Next, cells were fixed using
206 Cytotfix/Cytoperm buffer (BD Biosciences, CA) for 20 minutes at room temperature, and then kept in
207 FACS buffer at 4°C overnight. 1x Perm/Wash (BD Biosciences, CA) was used for cells permeabilization for
208 10 minutes at room temperature and followed by intracellular staining for 30 minutes at room
209 temperature with AF647 anti-human IFN γ (clone 4S.B3) and AF488 anti- human IL-2 (clone MQ1-17H12)
210 from Biolegend, and PE/Cy7 anti- human TNF α (clone Mab11) from Thermo Fisher Scientific. Up to
211 100,000 live CD3⁺ T cells were acquired on a LSRFortessa flow cytometer (BD Biosciences), equipped with
212 FACS Diva software. Analysis of the acquired data was performed using FlowJo software (version 10.7.1).
213 The background from each participant was removed by subtracting the % of spike⁺ cells to the % of
214 DMSO⁺ cells. An arbitrary value below 0.01% of CD4⁺/CD8⁺ T cells was considered negative.

215

216 **Statistical analysis**

217

218 The SARS-CoV-2 convalescent individual was excluded in all statistical analyses. Non-parametric
219 Spearman rank correlation was used to check for possible associations at single blood sample
220 measurements. A paired t-test was used to compare the adverse event scores calculated for each
221 participant after both vaccinations. For this, the individual mean differences were checked for normal
222 distribution by means of QQ-plots and histograms. A comparison of participants receiving heterologous
223 vaccination with controls who received homologous BNT162b2 vaccinations after the last blood sample
224 measurements was done by the Mann-Whitney-U test because of skewed distributions for neutralization
225 scores as well as IgM/IgG measurements. Longitudinal antibody measurements were analyzed by means
226 of a mixed linear regression model including a random intercept in order to account for the repeated
227 measures structure of the underlying data. The mixed linear model approach enabled to simultaneously
228 account for possible confounding due to participants' sex and for the presence of missing data ²⁶.
229 Therefore, no formal imputation of missing interim values was required. A two-sided alpha error of 5%
230 was applied to analyses. Analysis of repetitive measurements of sera provided by a cohort of 26
231 participants can be considered statistically valid. All analyses were done by GraphPad Prism version 9.1.1
232 for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com, R (version 4.0.1) and
233 SAS (version 9.4).

234


235

236 **Results:**

237 Reactogenicity following prime and boost vaccination was evaluated by all study participants by self-
238 reporting of solicited local and systemic symptoms according to a standardized questionnaire. Symptom
239 severity (mild, moderate, severe) and duration (<1 h, few h, ~1 day, > 1 day) is reported for each
240 individual participant (Figure S1A) and percentage of participants (Figure 1A,B).

241 Both, prime and boost vaccination, induced mild to moderate solicited adverse reactions in most
242 participants with 88.4% (23/26) reporting at least one mild or moderate symptom following prime; 23/26
243 (88.4%) and 21/26 (80.8%) reporting at least one mild or moderate symptom following boost vaccination
244 (Figure 1A,B). Most common symptoms after prime vaccination with ChAdOx1 nCoV-19 were pain at
245 the injection site (92.3%), fatigue (80.8%), headache (73.1%), chills (61.5%), myalgia (61.5%) and fever
246 (61.5%). Following boost vaccination with BNT162b2, most participants again reported pain at the
247 injection site (84.6%) and fatigue (84.6%), but chills (19.2%), myalgia (38.5) and fever (19.2%) were less
248 common. 23% of participants (6/26) reported at least one severe symptom following prime, 15.4% (4/26)
249 after boost. Fatigue (7.7%) and headache (15.4% for prime, 3.8% for boost) were amongst symptoms
250 reported as severe for both doses, while myalgia was reported as severe by 11.5% of participants
251 following prime, but none after boost.

252 Comparing cumulative solicited adverse reaction (cSAR) scores, reactogenicity following prime with
253 ChAdOx1 nCoV-19 was significantly ($p = 0.005$) higher than following boost with BNT162b2 (cSAR
254 score median 11 and 6 respectively, Figure 1C). Individually, most participants (19/26, 73.07%) had
255 milder reaction to boost compared to prime. 6/26 (23.07%) of participants described more severe reactions
256 to boost vaccination (Figure S1B). A trend towards higher cSAR scores reported by female participants
257 was seen for both boost and prime vaccinations (Figure 1D,E). No correlation was observed between
258 participant age and reactogenicity (Figure S1C,D). Reactogenicity towards prime and boost vaccination
259 was weakly but significantly correlated (Figure 1F, $p = 0.039$).



261 **Fig. 1. Solicited adverse reactions following ChAdOx1 nCoV-19 prime and BNT162b2 boost vaccination.**
262 Percentages of participants with individual symptoms following prime (A) or boost (B) vaccination. Severity is
263 graded on a scale of 1-2 (for some symptoms) or 1-3 (for most), according to Common Terminology Criteria for
264 Adverse Events (US Department of Health and Human Services, Version 4.03)²². (C) Cumulative solicited
265 adverse reaction (cSAR) scores of all participants following prime and boost vaccination. For calculation of cSAR
266 scores, symptom gradings are summed and an additional score point is added for symptoms lasting more than 24 h.
267 Analysis of cSAR scores by (D, E) participant gender, and (F) comparison between cSAR scores following prime
268 and boost vaccination. The SARS-CoV-2 convalescent individual was excluded in all statistical analyses. Paired t-
269 test; ns not significant; ** p < 0.01

270
271 We collected sera from participants 2 days (-2) or on the same day (0) before vaccination, and at days 15 –
272 16, 30 – 37, and 53 – 57 after ChAdOx1 nCoV-19 prime, and days 6 - 11 and 14 – 19 after BNT162b2
273 boost (64 – 65 or 72 – 73 after prime, respectively) to determine antibody responses (Figure 2). Already
274 15-16 days after prime, 19/25 (76%) participants showed detectable anti-SARS-CoV-2-spike-IgG levels
275 and 17/25 (65%) detectable IgA levels (Figure 2A,B). IgG levels peaked after 30 - 37 days and were
276 detectable in 24/25 (96%) participants. Until days 53 – 57, IgG levels slightly decreased, consistent with
277 previous results after single ChAdOx1 nCoV-19 dose^{4,5}. IgA values were highest already at days 15-16
278 and became undetectable in 24 (92%) participants at days 53 - 57. Notably, only 6 - 11 days after the
279 BNT162b2 boost, IgG was detectable in all (100%) and IgA in 23 (92%) of 25 participants. Until day 14-
280 19 after boost (72-73 post ChAdOx1 nCoV-19), IgG and IgA were detectable in all participants. This
281 corresponds to an at least 3.7-fold increase in median IgG levels from pre-boost to 2 weeks post-boost. We
282 next quantified cumulative anti-SARS-CoV-2-spike-IgM and IgG concentrations and detected median
283 antibody levels of 3.39 (range 0-2,126) units per ml (U/ml) 15-16 days after prime vaccination in 22/25
284 (88%) participants (Figure 2C). From days 30 – 37 on, IgM and IgG were detected in all participants and
285 medians continuously increased to 28 (1.86-1,436) and 63.9 (4.27-1,005) U/ml after days 30 - 37 or 53 -
286 57, respectively. After BNT162b2 boost, titers increased 134-fold to 8,614 (126 – 24,831) at days 6 – 11
287 and 135-fold to 8,815 (1,206 – 19,046) 14 - 19 days after the second dose. Strikingly, the resulting titers
288 were 8.1-fold higher than those determined for sera obtained after 13-15 days of a homologous BNT162b2
289 boost (individuals with median age 41 (25-55); median titers 1,086; range 498-3,660). Cumulative IgM/G
290 titers correlated with IgG titers at each timepoint analysed post prime (Figure S2, Table S1).


291 Sera were also evaluated for their potential to inhibit SARS-CoV-2-spike-receptor binding domain/ACE2
292 interaction using a surrogate virus neutralisation test (sVNT) (Figure 2D). 15-16 days after ChAdOx1
293 nCoV-19 administration 13/25 (52%) participant sera showed ACE2 neutralizing activity, correlating
294 significantly with IgG and IgM/G titers (Figure S2, Table S1). Median neutralization activity of the
295 positive sera was 46% (range 32-97%). Until days 53-57, the number of participants with neutralizing sera
296 increased to 19/26 (73%) and the median ACE2 neutralization to 62% (range 32-95%), again in
297 correlation with IgG and IgM/G values (Figure S2, Table S1). After BNT162b2 boost, all participants
298 showed potent neutralization with a median of 97% (range 32-98%) after 6-11, and 98% (range 89-98%)
299 after 14-16 days suggesting a strong and functional antibody response after heterologous vaccination in all
300 participants.

301 The potency of neutralizing activity was further quantified using vesicular stomatitis virus (VSV)-based
302 pseudoviruses carrying the SARS-CoV-2 spike protein of the most prevalent SARS-CoV-2 B.1.1.7
303 variant. This system faithfully recapitulates SARS-CoV-2 entry into cells and its inhibition^{21,27,28}. 15-16
304 days after ChAdOx1 nCoV-19 prime, neutralizing titers ranging from 36-906 were detectable in 8/25
305 (32%) participants (Figure 2E). The number of participants with detectable neutralization increased to
306 maximum in 12/25 (48%) individuals at days 30-37 with a median neutralization titer of 74 (range 20-

307 552) in responders, which slightly decreased until days 53-58. Two weeks after the BNT162b2 boost,
 308 neutralizing titers were detected in all participants with a median titer of 2,744 (range 209-8,985). Of note,
 309 while for some individuals the titers further increased from week 1 to week 2 after BNT162b2 boost, other
 310 individuals plateaued at titers > 1,000 (Figure S3). At all time points, neutralizing activity correlated with
 311 IgG or IgM/G titers (Figure S2, Table S1). Remarkably, the median titer of these individuals was 3.9-fold
 312 higher than the median titer of 14 individuals vaccinated with BNT162b2 in a homologous regimen (709;
 313 range 305-1,806) suggesting a stronger humoral protection after a heterologous vaccination. Of note, a
 314 SARS-CoV-2 convalescent individual (triangle symbol) showed a strong response after the first dose in all
 315 assays, high IgG, IgA or IgM/G values, most effective ACE2- neutralization and a high neutralization titer
 316 of 906 15 – 16 days after prime that decreased over the days to 201 at day 53-57 (Figure 2A-E).

317 Additionally, we evaluated the neutralizing activities of sera obtained 2 weeks post full vaccination
 318 against the variants of concern (VOCs) B.1.351 and B.1.617. Pseudovirus entry driven by B.1.351 spike
 319 was neutralized with 2-fold lower potency ($p < 0.05$) compared to B.1.1.7 spike. However, it was still
 320 entirely blocked at higher doses with a median titer of 1,297 (range 252 - 6,523). Neutralization of the
 321 B.1.617 spike was not reduced compared to B.1.1.7 spike (median titer of 1,309; range 150 – 13,252)
 322 (Figure 2F). Sera of individuals vaccinated with homologous BNT162b2 showed lower neutralizing titers
 323 against all spike variants tested (Figure 2F), suggesting stronger humoral protection after a heterologous
 324 vaccination also against VOCs.

325




326

327 **Fig. 2. Humoral response.** Quantification of anti-SARS-CoV-2 S1 spike domain (A) IgG and (B) IgA titers. (C)
 328 Quantification of anti-SARS-CoV-2 spike IgG and IgM responses as units per ml (U/ml) by immunoassay. (D)

329 SARS-CoV-2 surrogate virus ACE2 neutralization test. (E) VSV-based B.1.1.7 SARS-CoV-2 spike pseudovirus
330 neutralization assay. (F) VSV-based B.1.1.7, B.1.351 and B.1.617-SARS-CoV-2 spike pseudovirus neutralization
331 assay. Titers expressed as serum dilution resulting in 50% pseudovirus neutralization (PVNT50). Triangle indicates
332 SARS-CoV-2 convalescent individual, who was excluded from all statistical analyses. Grey symbols indicate
333 datapoints pre-vaccination, red datapoints indicate datapoints after prime and light-blue after boost vaccination.
334 Dark-blue indicates samples of participants with homologous BNT162b2 prime-boost regimen. Dashed horizontal
335 lines indicate upper and lower limit of detection/cutoff, respectively. Dashed vertical lines indicate prime and boost
336 vaccination. Longitudinal antibody measurements were analyzed by means of a mixed linear regression model.
337 Mann-Whitney-U test compares ChAdOx1 nCoV-19 and BNT162b2 titers *** $p < 0.0001$, ** $p < 0.001$, * $p < 0.05$,
338 ns not significant

339
340 To evaluate cellular immunity, we isolated peripheral blood mononuclear cells from blood samples
341 provided by 19/26 participants on days 14-19 post BNT162b2 boost (72-73 days post prime), considered
342 as full vaccination according to the vaccination schedule. Cells were exposed to a SARS-CoV-2 spike-
343 spanning peptide-pool and analyzed for intracellular cytokines TNF α , IFN γ , and IL2 to determine spike-
344 specific CD4⁺ and CD8⁺ T cell responses (Figure 3, S4). Upon antigen stimulation, CD4⁺ T cells secreting
345 IFN γ (median 0.055, range 0.018-0.168), IL2 (median 0.055, range 0-0.134) or TNF α (median 0.057;
346 range 0.01 – 0.193) were detected in all participants suggesting they developed a robust spike-specific T
347 helper 1 (TH1) CD4⁺ T cell response. In addition, in 89% (17/19) of participants a substantial population
348 of spike-specific CD8⁺ T cells, with a predominant IFN γ ⁺ (median 0.092, range 0-0.665) and TNF α ⁺
349 (median 0.055, range 0 – 0.375) phenotype was detected. We observed lower levels of CD8⁺ IL2⁺ (median
350 0.01, range 0-0.052) T cells which is in agreement with responses after homologous BNT162b2
351 vaccination ⁶. Interestingly, unstimulated CD8⁺ T cells of the convalescent individual were already
352 reactive before SARS-CoV-2 spike peptide stimulation. Overall, these findings show a robust humoral and
353 cellular immune response after heterologous vaccination.



355
356 **Fig. 3. SARS-CoV-2 spike-specific CD4⁺ and CD8⁺ T cell responses.** PBMCs of study participants were
357 stimulated with a SARS-CoV-2 spike peptide-pool and cytokine secretion determined by flow cytometry. Cytokine⁺
358 T cells were background corrected for unstimulated cells and values lower than 0.01% were considered negative.
359 Triangle symbol indicates SARS-CoV-2 convalescent individual, where cytokine release was already high in
360 absence of stimulation.

361

363 Discussion

364 Based on the regulatory approvals for ChAdOx1 nCoV-19 and mRNA vaccines, the interval between
365 prime and boost vaccinations ranges between 4 -12 weeks²⁹⁻³¹. For ChAdOx1 nCoV-19, a 12 week
366 interval has been shown to result in stronger immune responses³², most likely because the immunity
367 against the vector wanes. Accordingly, e.g. in Germany heterologous vaccinations are currently typically
368 performed after 12 weeks. Existing vector immunity, however, is irrelevant in the context of a mRNA
369 boost vaccination, on which basis our cohort received the boost after 8 weeks. This heterologous
370 ChAdOx1 nCoV-19/BNT162b2 vaccination elicited strong IgM/G and IgA responses, neutralizing
371 activities and T cell responses in all previously uninfected participants, while solicited adverse reactions to
372 vaccination were as expected for a prime ChAdOx1 nCoV-19 vaccination and reduced following
373 heterologous BNT162b2 boost.

374 A previous study showed that a heterologous vaccination schedule with 4-week interval results in stronger
375 reactogenicity after boost¹⁶, whereas a preprinted study with a 12-week interval did not confirm this effect
376¹⁷. We did not directly compare different vaccination schemes. Thus, we cannot draw definitive
377 conclusions on differences, which might also depend on cohort age⁵. With an 8-week interval, we
378 observed an overall milder reactogenicity following heterologous boost with BNT162b2 than after initial
379 prime vaccination with ChAdOx1 nCoV-19 and no serious adverse events, arguing for the safety of this
380 regimen in young adults.

381 Our immunological data suggest that a heterologous vector-based/mRNA prime-boost schedule is highly
382 effective in preventing COVID-19, as neutralizing antibody levels correlate with immune protection from
383 symptomatic SARS-CoV-2 infection³³ and CD8⁺ T cell responses have been associated with a mild
384 disease course^{34,35}. Endpoint antibody titers determined 2 weeks post boost were significantly higher than
385 those detected upon homologous BNT162b2 vaccinations (Figure 2 C,E). This is in line with findings in
386 preclinical models¹⁸, but might also be influenced by cohort age. Factors contributing to this high degree
387 of immunogenicity might be the circumvention of vector immunity. The BNT162b2 encoded spike
388 sequence contains a two-proline mutation not present in ChAdOx1 nCoV-19, which fix spike in a pre-
389 fusion confirmation⁹. It is tempting to speculate that altered spike confirmations may be beneficial for
390 effective neutralizing responses.

391 Neutralizing activity towards VOC B.1.351, previously reported to show partial evasion of vaccination-
392 induced antibodies^{21,36,37}, was only slightly decreased following heterologous vaccination. Neutralization
393 of emerging VOC B.1.617 was not reduced compared to B.1.1.7. Whether these immunological findings
394 translate into effective general protection from VOCs in real-life setting remains to be determined.
395 However, the substantial neutralization capacity against two highly transmissible virus variants is
396 encouraging.

397 Secretory IgA responses at the mucosal site of SARS-CoV-2 entry are of particular interest with regard to
398 prevention of virus transmission and (re-)infection³⁸. We detected a general increase in serum IgA levels
399 with strong variation between participants, suggesting mucosal protection shortly after vaccination.
400 However, IgA levels decreased over time after prime vaccination, and future studies, especially assessing
401 IgA and secretory IgA levels and persistence at mucosal entry sites after boost are warranted.

402 In all participants SARS-CoV-2 specific CD8⁺ or CD4⁺ T cells were detected 2 weeks after full
403 vaccination. These effects were similar to those reported after a single ChAdOx1 nCoV-19 dose and after
404 homologous BNT162b2 vaccination^{4,6}. This suggests that T cell responses are similarly effective after
405 heterologous vaccination.

406 In line with previous results, in an individual participant who was previously tested SARS-CoV-2
407 positive, a single prime vaccination dose already elicited strong antibody responses^{39,40}. In this case, the
408 observed neutralizing titers 2 weeks after prime were as high as the median titer of those receiving the
409 homologous BNT162b2 vaccination. However, titers (IgM/G) further increased 8-fold after boost,
410 suggesting that prime-boost might provide more potent and longer lasting protection.

411 In conclusion, heterologous vaccination schedule of ChAdOx1 nCov-19 prime, followed by BNT162b2
412 boost after 8 weeks for participants with a median age of 30 years was safe and effective. This provides
413 flexibility for future vaccination strategies and will be useful for vaccine schedules during shortages.
414 Whether heterologous vaccination is superior to homologous regimens and should be considered as a
415 strategy to elicit particularly strong immune responses e.g. against VOCs or for highly exposed
416 individuals remains to be determined. Similarly, whether other vector- or mRNA-based vaccine
417 combinations or those based on other technologies are similarly effective needs to be addressed in future
418 studies.

419 Limitations

420 The study cohort of 26 participants is not large, but the repetitive measurements suffice for a
421 comprehensive analysis of serological responses. With a median age of 30.5 (range 25 - 46) years, the
422 results do not provide information on the elderly. However, our study offers insight into how the younger
423 age group reacts to a heterologous vaccination regimen. This is of high significance, because individuals
424 younger than 60 have regularly been primed with ChAdOx1 nCov-19 and are now offered heterologous
425 boost vaccination. Our study group received the second vaccination after 8 weeks, which is within the
426 range of recommendation of 4-12 weeks.

427

428 Acknowledgments:

429 We thank all participants for regular blood donations. We thank Nicola Schrott, Regina Burger, Jana
430 Romana Fischer, Birgit Ott, Carolin Ludwig, Katrin Ring, Nadine Pfeifer, Maxine Rustler, Vivien Prex
431 for skillful laboratory assistance. We thank Sarah Warth, Simona Ursu, and Christian Buske of the flow
432 cytometry core facility for support with flow cytometric analysis. We thank the Robert Koch Institute
433 (RKI) for financial support. This project has received funding from the European Union's Horizon 2020
434 research and innovation programme under grant agreement No 101003555 (Fight-nCoV) to J.M., the
435 German Research Foundation (CRC1279) to F.K. and J.M., the BMBF to F.K. (Restrict SARS-CoV-2)
436 and an individual research grant (to J.A.M.). J.A.M. is indebted to the Baden-Württemberg Stiftung for the
437 financial support of this research project by the Eliteprogramme for Postdocs. R.G., A.S., and C.C. are
438 part of the International Graduate School in Molecular Medicine Ulm. S.P. received funding from BMBF
439 (01KI1723D, 01KI20328A, 01KI20396, 01KX2021) and the county of Lower Saxony (14-76103-184,
440 MWK HZI COVID-19). H.S. acknowledges funding from the Ministry for Science, Research and the Arts
441 of Baden-Württemberg, Germany and the European Commission (HORIZON2020 Project SUPPORT-E,
442 no. 101015756).

443

444 **References:**


- 445 1. World Health Organization. *Pneumonia of unknown cause – China*.
446 <https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/> (2020).
- 447 2. World Health Organization. *Coronavirus disease 2019 (COVID-19) Situation Report - 75*.
448 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports> (2020).
- 449 3. Mathieu, E. *et al.* A global database of COVID-19 vaccinations. *Nat. Hum. Behav.*
450 2021.03.22.21254100 (2021) doi:10.1038/s41562-021-01122-8.
- 451 4. Ewer, K. J. *et al.* T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19
452 (AZD1222) vaccine in a phase 1/2 clinical trial. *Nat. Med.* **27**, 270–278 (2021).
- 453 5. Folegatti, P. M. *et al.* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against
454 SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*
455 **396**, 467–478 (2020).
- 456 6. Sahin, U. *et al.* BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans.
457 *medRxiv* (2020) doi:10.1101/2020.12.09.20245175.
- 458 7. Ramasamy, M. N. *et al.* Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered
459 in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised,
460 controlled, phase 2/3 trial. *Lancet* **396**, 1979–1993 (2020).
- 461 8. Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
462 SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and
463 the UK. *Lancet* **397**, 99–111 (2021).
- 464 9. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J.*
465 *Med.* **383**, 2603–2615 (2020).
- 466 10. Haas, E. J. *et al.* Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2

- 467 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination
468 campaign in Israel: an observational study using national surveillance data. *Lancet* **397**, 1819–1829
469 (2021).
- 470 11. Vasileiou, E. *et al.* Interim findings from first-dose mass COVID-19 vaccination roll-out and
471 COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet* **397**,
472 1646–1657 (2021).
- 473 12. European Medicines Agency. *AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very*
474 *rare cases of unusual blood clots with low blood platelets.*
475 [https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-](https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood)
476 [rare-cases-unusual-blood-clots-low-blood](https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood) (2021).
- 477 13. Greinacher, A. *et al.* Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N.*
478 *Engl. J. Med.* NEJMoa2104840 (2021) doi:10.1056/NEJMoa2104840.
- 479 14. Pottegård, A. *et al.* Arterial events, venous thromboembolism, thrombocytopenia, and bleeding
480 after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population
481 based cohort study. *BMJ* n1114 (2021) doi:10.1136/bmj.n1114.
- 482 15. Robert Koch Institut. *Epidemiologisches Bulletin.*
483 https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/16_21.html (2021).
- 484 16. Shaw, R. H. *et al.* Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
485 *Lancet* **6736**, 19–21 (2021).
- 486 17. Hillus, D. *et al.* Reactogenicity of homologous and heterologous prime-boost immunisation with
487 BNT162b2 and ChAdOx1-nCoV19: a prospective cohort study. *medRxiv* 2021.05.19.21257334
488 (2021) doi:10.1101/2021.05.19.21257334.
- 489 18. He, Q. *et al.* Heterologous prime-boost: breaking the protective immune response bottleneck of

- 490 COVID-19 vaccine candidates. *Emerg. Microbes Infect.* **10**, 629–637 (2021).
- 491 19. Hoffmann, M. *et al.* SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades
492 antibodies induced by infection and vaccination. *bioRxiv* 2021.05.04.442663 (2021)
493 doi:10.1101/2021.05.04.442663.
- 494 20. Althaus, K. *et al.* Antibody-mediated procoagulant platelets in SARS-CoV-2- vaccination
495 associated immune thrombotic thrombocytopenia. *Haematologica* (2021)
496 doi:10.3324/haematol.2021.279000.
- 497 21. Hoffmann, M. *et al.* SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
498 *Cell* **184**, 2384-2393.e12 (2021).
- 499 22. National Cancer Institute (U.S.). Common terminology criteria for adverse events □: (CTCAE).
500 (2010).
- 501 23. Kleine-Weber, H., Elzayat, M. T., Hoffmann, M. & Pöhlmann, S. Functional analysis of potential
502 cleavage sites in the MERS-coronavirus spike protein. *Sci. Rep.* **8**, 16597 (2018).
- 503 24. Berger Rentsch, M. & Zimmer, G. A Vesicular Stomatitis Virus Replicon-Based Bioassay for the
504 Rapid and Sensitive Determination of Multi-Species Type I Interferon. *PLoS One* **6**, e25858
505 (2011).
- 506 25. Kasturi, S. P. *et al.* 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–
507 specific plasma cells and humoral immunity in nonhuman primates. *Sci. Immunol.* **5**, eabb1025
508 (2020).
- 509 26. European Medicines Agency. *Missing data in confirmatory clinical trials.*
510 <https://www.ema.europa.eu/en/missing-data-confirmatory-clinical-trials> (2010).
- 511 27. Jahrsdörfer, B. *et al.* Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–
512 Convalescent Donors. *J. Immunol.* **206**, 2614–2622 (2021).

- 513 28. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by
514 a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8 (2020).
- 515 29. European Medicines Agency. *EMA recommends COVID-19 Vaccine AstraZeneca for*
516 *authorisation in the EU*. EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in
517 the EU (2021).
- 518 30. European Medicines Agency. *EMA recommends COVID-19 Vaccine Moderna for authorisation in*
519 *the EU*. (2021) doi:[https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-](https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu)
520 [moderna-authorisation-eu](https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu).
- 521 31. European Medicines Agency. *Comirnaty*.
522 <https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty#authorisation-details-section>
523 (2021).
- 524 32. Voysey, M. *et al.* Single-dose administration and the influence of the timing of the booster dose on
525 immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four
526 randomised trials. *Lancet* **397**, 881–891 (2021).
- 527 33. Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from
528 symptomatic SARS-CoV-2 infection. *Nat. Med.* (2021) doi:10.1038/s41591-021-01377-8.
- 529 34. Peng, Y. *et al.* Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK
530 convalescent individuals following COVID-19. *Nat. Immunol.* **21**, 1336–1345 (2020).
- 531 35. Sekine, T. *et al.* Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild
532 COVID-19. *Cell* **183**, 158-168.e14 (2020).
- 533 36. Zhou, D. *et al.* Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-
534 induced sera. *Cell* **184**, 2348-2361.e6 (2021).
- 535 37. Madhi, S. A. *et al.* Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351


- 536 Variant. *N. Engl. J. Med.* **384**, 1885–1898 (2021).
- 537 38. Sterlin, D. *et al.* IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Sci.*
538 *Transl. Med.* **13**, eabd2223 (2021).
- 539 39. Krammer, F. *et al.* Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-
540 2 mRNA Vaccine. *N. Engl. J. Med.* **384**, 1372–1374 (2021).
- 541 40. Frieman, M. *et al.* SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors.
542 *EBioMedicine* **68**, 103401 (2021).
- 543
- 544



545

546 **Figure S1: Extended analysis of solicited adverse reactions following ChAdOx1 nCoV-19 prime and**
 547 **BNT162b2 boost vaccination.** (A) Heatmap showing SAR scores per participant and symptom used for calculation
 548 of cSAR scores. Severity is graded on a scale of 1-2 (for some symptoms) or 1-3 (for most), according to Common
 549 Terminology Criteria for Adverse Events (US Department of Health and Human Services, Version 4). For
 550 calculation of cSAR score (A, B), symptom gradings are summed and an additional score point is added for
 551 symptoms lasting more than 24 h (final scores 1-4 per symptom). Correlation analysis for cSAR scores with
 552 participant age for prime (C) and boost (D) vaccination.

553



554

555

556 **Figure S2. Correlation analysis of humoral response metrics.** Data on humoral response (IgG, IgA, IgM/G, PVNT50,
 557 Inhibition SARS-CoV-2-sVNT) were analysed for correlation for each timepoint. Spearman correlation, two-tailed p
 558 values, dashed lines indicate 95% confidence interval. The SARS-CoV-2 convalescent individual was excluded from
 559 the analysis.

560


561 **Table S1. Summary of correlation analysis of humoral response metrics.** Spearman r values of Figure S2.

562

563

	-2 - 0	15 – 16	30 - 37	53 - 57	64 - 65	72 - 73
IgG:IgM/G	/	0.87	0.9235	0.9692	0.821	0.619
sVNT:IgG	-0.0084	0.848	0.881	0.957	0.478	0.296
sVNT:IgM/G	/	0.686	0.9139	0.9554	0.4583	0.656
PVNT50:IgM/G	/	0.6651	0.836	0.6626	0.9191	0.6423
PVNT50:IgG	/	0.6453	0.799	0.6782	0.8294	0.6374


564



565

566 **Figure S3. Time course of humoral responses.** Time course of anti-SARS-CoV-2 S1 spike domain (A) IgG and (B) IgA
567 titers. (C) Time course of anti-SARS-CoV-2 spike IgG and IgM responses as units per ml (U/ml) by immunoassay. (D)
568 Time course of SARS-CoV-2 surrogate virus ACE2-RBD interaction neutralization as assessed by surrogate virus
569 neutralisation test (sVNT). (E) VSV-based B.1.1.7 SARS-CoV-2 spike pseudovirus neutralization assay. Titers
570 expressed as serum dilution resulting in 50% pseudovirus neutralization (PVNT50).

571



572

573

574

575

576

577

578

579

Figure S4. Gating strategy for analysis of T cell reactivity. SARS-CoV-2 spike peptide stimulated and unstimulated (DMSO) PBMCs were initially gated on the basis of light scatter (SSC-A versus FSC-A) and for singlets (FSC-H versus FSC-A). Dead cells, monocytes, and B cells were excluded using a dump channel and by gating on CD3⁺ T cells. Total CD8⁺ and CD4⁺ cells were then selected, and individual cytokine gating was performed.